tiprankstipranks
Trending News
More News >
Wakamoto Pharmaceutical Co., Ltd. (JP:4512)
:4512
Japanese Market
Advertisement

Wakamoto Pharmaceutical Co., Ltd. (4512) Price & Analysis

Compare
0 Followers

4512 Stock Chart & Stats


4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥209.00 and its highest was ¥377.00 in the past 12 months.
    What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?
    Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥10.62B.
      When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?
      Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 05, 2025 which is in 85 days.
        How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?
        Wakamoto Pharmaceutical Co., Ltd. released its earnings results on Aug 01, 2025. The company reported -¥3.125 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.125.
          Is Wakamoto Pharmaceutical Co., Ltd. overvalued?
          According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?
            Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3 which represents an annual dividend yield of 0.98%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here
              What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?
              Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?
              Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.
                What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
                Wakamoto Pharmaceutical Co., Ltd. reported an EPS of -¥3.125 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?
                  Currently, no hedge funds are holding shares in JP:4512

                  Company Description

                  Wakamoto Pharmaceutical Co., Ltd.

                  Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.

                  Wakamoto Pharmaceutical Co., Ltd. (4512) Earnings & Revenues

                  4512 Stock 12 Month Forecast

                  Average Price Target

                  ¥292.00
                  ▼(-4.58% Downside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"212":"¥212","271":"¥271","330":"¥330","241.5":"¥241.5","300.5":"¥300.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":292,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥292.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":292,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥292.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":292,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥292.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[212,241.5,271,300.5,330],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,304,303.0769230769231,302.15384615384613,301.2307692307692,300.3076923076923,299.38461538461536,298.46153846153845,297.53846153846155,296.61538461538464,295.6923076923077,294.7692307692308,293.84615384615387,292.9230769230769,{"y":292,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,304,303.0769230769231,302.15384615384613,301.2307692307692,300.3076923076923,299.38461538461536,298.46153846153845,297.53846153846155,296.61538461538464,295.6923076923077,294.7692307692308,293.84615384615387,292.9230769230769,{"y":292,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,304,303.0769230769231,302.15384615384613,301.2307692307692,300.3076923076923,299.38461538461536,298.46153846153845,297.53846153846155,296.61538461538464,295.6923076923077,294.7692307692308,293.84615384615387,292.9230769230769,{"y":292,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":244.75,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":245.74,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":265.56,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":230.88,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":236.82,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":221.96,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":213.04,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":302.22,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":312,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":329,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":329,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":301,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":304,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Morishita Jintan Co., Ltd.
                  Fuso Pharmaceutical Industries,Ltd.
                  Nippon Chemiphar Co., Ltd.
                  Taiko Pharmaceutical Co., Ltd.
                  Symbio Pharmaceuticals Limited

                  Ownership Overview

                  99.94%
                  Insiders
                  Mutual Funds
                  ― Other Institutional Investors
                  99.94% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis